Faruqi & Faruqi, LLP Assists Investors Seeking Legal Action Against LifeMD

Legal Action for LifeMD Investors

Faruqi & Faruqi, LLP, a prominent national securities law firm, has opened an investigation into the claims affecting investors of LifeMD, Inc. This initiative comes in response to significant losses suffered by stakeholders in LifeMD between May 7, 2025, and August 5, 2025. Investors are encouraged to reach out to Senior Partner, James (Josh) Wilson for further discussion about their legal rights and available options regarding possible claims against LifeMD.

Background on LifeMD

LifeMD operates within the healthcare sector, focusing primarily on providing telehealth and online prescribing services. The company has been listed on the NASDAQ under the ticker LFMD. In recent months, however, LifeMD has faced scrutiny over its operational integrity and financial disclosure. Alarmingly, on August 5, 2025, LifeMD revealed significant downward revisions to its previously issued revenue guidance, which raised red flags among investors.

Allegations of Securities Fraud

The allegations against LifeMD include making misleading statements and failing to disclose critical information that might have affected stock performance. Specifically, the complaint claims:

1. LifeMD and its executives overstated the company's competitive positioning in the market.
2. In raising its 2025 revenue guidance, the management neglected crucial metrics, particularly concerning rising customer acquisition costs in its RexMD segment.
3. The executives’ statements lacked a reasonable basis and misrepresented the company’s operational status and future prospects.

As a direct consequence of these alleged misrepresentations, shares of LifeMD saw a drastic decrease of 44.8% following the revenue guidance announcement.

Call to Action for Affected Investors

For anyone who experienced financial losses related to LifeMD during the specified period, it is crucial to seek legal counsel before the upcoming deadline to engage as a lead plaintiff in a federal securities class action. The firm reminds potential claimants that the lead plaintiff is tasked with representing the broader class in ongoing litigation, and existing shareholders can opt to participate or remain passive without affecting their recovery in any settlement.

Josh Wilson is available for direct contact through the provided phone numbers — 877-247-4292 or 212-983-9330 (Ext. 1310) — to assist in navigating the complexities of this situation. The firm is particularly interested in speaking with whistleblowers, former employees, or anyone possessing relevant information regarding LifeMD’s misconduct.

Moreover, those interested in learning more about the ongoing legal processes can visit the dedicated page on Faruqi & Faruqi's website at www.faruqilaw.com/LFMD. Should you choose to take action, the firm assures that all communications will be handled with the utmost confidentiality.

Conclusion

Faruqi & Faruqi, LLP has established a notable reputation for advocating on behalf of investors, having recovered substantial financial losses for clients since its inception in 1995. With offices situated across New York, Pennsylvania, California, and Georgia, it remains committed to representing the interests of investors nationwide. If you’ve encountered losses in LifeMD, this is an urgent call to action for potential legal recourse. Don't miss the opportunity to protect your rights and recover losses that you may have incurred as an investor in LifeMD.